Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J McIntyre

Showing results (411-420 of 438) with videos related to

Pageof 44
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonistsCharles J McIntyre, John A McCauley, Bohumil Bednar, et al.
Cell Communication and Signaling : CCS|September 26, 2024
A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancersCharlotte Zoe Angel, Shannon Beattie, Ezanee Azlina Mohamad Hanif, et al.
Anaesthesia and Intensive Care|June 2, 2016
The effect of augmenting early nutritional energy delivery on quality of life and employment status one year after ICU admissionD B Reid, L S Chapple, S N O'Connor, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 16, 2011
Tuberculosis in HIV programmes in lower-income countries: practices and risk factorsL Fenner, M Forster, A Boulle, et al.
Angewandte Chemie (International Ed. in English)|October 18, 2008
Bismacrocyclic inhibitors of hepatitis C NS3/4a proteaseJohn A McCauley, Michael T Rudd, Kevin T Nguyen, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2010
Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channelDouglas C Beshore, Nigel J Liverton, Charles J McIntyre, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|November 28, 2006
Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillationB Wesley Trotter, Kausik K Nanda, Nathan R Kett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Stephen Jones, Frankie Ann Holmes, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerStephen E Jones, Michael A Savin, Frankie Ann Holmes, et al.
Pageof 44

Showing results (411-420 of 438) with videos related to

Sort By:
Pageof 44
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonistsCharles J McIntyre, John A McCauley, Bohumil Bednar, et al.
Cell Communication and Signaling : CCS|September 26, 2024
A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancersCharlotte Zoe Angel, Shannon Beattie, Ezanee Azlina Mohamad Hanif, et al.
Anaesthesia and Intensive Care|June 2, 2016
The effect of augmenting early nutritional energy delivery on quality of life and employment status one year after ICU admissionD B Reid, L S Chapple, S N O'Connor, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 16, 2011
Tuberculosis in HIV programmes in lower-income countries: practices and risk factorsL Fenner, M Forster, A Boulle, et al.
Angewandte Chemie (International Ed. in English)|October 18, 2008
Bismacrocyclic inhibitors of hepatitis C NS3/4a proteaseJohn A McCauley, Michael T Rudd, Kevin T Nguyen, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2010
Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channelDouglas C Beshore, Nigel J Liverton, Charles J McIntyre, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|November 28, 2006
Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillationB Wesley Trotter, Kausik K Nanda, Nathan R Kett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Stephen Jones, Frankie Ann Holmes, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerStephen E Jones, Michael A Savin, Frankie Ann Holmes, et al.
Pageof 44